Abstract
The family of cell division cycle 25 (CDC25) phosphatase is one of the important regulators of the cell cycle progression. In mammalian cells, three isoforms have been identified: CDC25A, CDC25B, and CDC25C. CDC25A is required to enter S time, and the overexpression of this phosphatase accelerates the entrance to S time. CDC25A overexpression could render tumor cells less sensitive to DNA replication checkpoints, thereby contributing to their genomic instability. We aimed to investigate, for the first time, the frequency of human CDC25A gene SNPs in metastatic and non-metastatic breast cancer. Total number of 281 eligible patients with histologically confirmed incident of breast cancer and 137 cancer-free controls were included. The detection of CDC25A gene polymorphisms was achieved with real-time polymerase chain reaction and restriction fragment length polymorphism techniques. We found that the 263C/T polymorphism was significantly associated with breast cancer and risk of metastasis. The -350C/T polymorphism in the promoter region of CDC25A gene was found to associate with neither breast cancer nor metastasis. The other promoter polymorphism -51C/G in the CDC25A gene associated with breast cancer but not associated with metastasis. These data suggest that 263C/T and -51C/G polymorphisms of CDC25A gene could be candidate markers for earlier diagnosis and targets for breast cancer therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gürtunç E: Meme Kanserli Hastalarda CYP19 Geni Kodon 39 Trp/Arg Polimorfizminin ve Genotip Dağılımının Araştırılması. Yüksek Lisans Tezi. Çukurova Üniv Sağlık Bilimleri Ens Tıbbi Biyoloji ABD 2007.
Yıldız Y: Meme Kanserli Hastalarda TNF ile İlişkili Apoptoz Uyarıcı Ligand ve Bcl-2 ile İlişkili X-Protein Gen Polimorfizmlerinin Araştırılması. Yüksek Lisans Tezi. İstanbul Üniv Sağlık Bilimleri Ens Moleküler Tıp ABD 2008.
Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett. 2006;240:261–7.
Hossfeld DK, Sherman CD, Love RR, Bosch FX: Klinik Onkoloji. Uluslararası Kanserle Savaş Birliği 1992; 5th edition, p 25.
Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? good targets? Nat Rev Cancer. 2007;7:495–507.
Cangi MG, Cukor B, Soung P, Signoretti S, Moreira Jr G, Ranashinge M, et al. Role of the CDC25A phosphatase in human breast cancer. J Clin Invest. 2000;106:753–61.
Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H, et al. CDC25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 1994;13:1549–56.
Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human CDC25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 1994;13:4302–10.
Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol. 2006;18:185–91.
Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF. Human CDC25A inactivation in response to S time inhibition and its role in preventing premature mitosis. EMBO Rep. 2000;1:71–9.
Gasparotto D, Maestro R, Piccinin S, Vukosavljevic T, Barzan L, Sulfaro S, et al. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 1997;57:2366–8.
Hernandez S, Hernandez L, Bea S, Cazorla M, Fernandez PL, Nadal A, et al. CDC25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin’s lymphomas. Cancer Res. 1998;58:1762–7.
Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, et al. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res. 1997;88:947–52.
Wu W, Fan Y, Kemp B, Walsh G, Mao L. Overexpression of CDC25A and CDC25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 1998;58:4082–5.
Moreira Jr G, Colleoni GWB, Cangi MG, Murphy M, Sherburne B, et al. Reciprocal CDC25A and p27 expression in B-cell non-Hodgkin lymphomas. Diagn Mol Pathol. 2003;12(3):128–32.
Hernandez S, Bessa X, Bea S, Hernandez L, Nadal A, Mallofre C, et al. Differential expression of CDC25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab Invest. 2001;81:465–73.
Ray D, Kiyokama H. CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res. 2008;68(5):1251–3.
Cangi MG, Piccinin S, Pecciarini L, Talarico A, Cin ED, Grassi S, et al. Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites. Int J Cancer. 2008;123:1466–71.
http://atlasgeneticsoncology.org/Genes/CDC25AID40004ch3p21.html (access date:18 May 2010)
Cozma D, Lukes L, Rouse J, Qiu TH, Liu ET, Hunter KW. A bioinformatics-based strategy identifies c-Myc and CDC25A as candidates for the Apmt mammary tumour latency modifiers. Genome Res. 2002;12:969–75.
Ito Y, Yoshida H, Uruno T, Takamura Y, Miya A, Kuma K, et al. Expression of CDC25A and CDC25B phosphatase in breast carcinoma. Breast Cancer. 2004;11:295–300.
Acknowledgments
The authors give their thanks to Dr. Celalettin Camci in the Department of Oncology, University of Gaziantep, in Gaziantep Turkey, for his valuable advise and cooperation in this research work.
Role of the funding source
This study was funded by the University of Gaziantep, Scientific Research Projects (GAUNBAP FEF 09.06, Gaziantep, Turkey).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Karagoz, I.D., Ozaslan, M., Cengiz, B. et al. CDC25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma. Tumor Biol. 31, 597–604 (2010). https://doi.org/10.1007/s13277-010-0075-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-010-0075-z